An industry perspective on tiered approach to the investigation of metabolites in drug development

Bioanalysis

Volumn 6, Issue 5, 2014, Pages 617-628

  Huskey, Su Er W ^a   Li, Wenkui ^a   Mangold, James B ^a   Flarakos, Jimmy ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CELLULOSE; DRUG METABOLITE; ENZYME INHIBITOR; NEW DRUG; POLYMER; DRUG; PHARMACOLOGICAL BIOMARKER;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BLOOD STORAGE; DRUG METABOLISM; HUMAN; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PH; PHOTODEGRADATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TEMPERATURE; WHOLE BODY AUTORADIOGRAPHY; BLOOD; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG SCREENING; METABOLISM; PROCEDURES;

BIOMARKERS, PHARMACOLOGICAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84896467043     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.25     Document Type: Article

References (41)

1. Isoherranen N, Hachad H, Yeung CK, Levy RH. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: Literature evaluation based on the metabolism and transport drug interaction database. Chem. Res. Toxicol. 22(2), 294-298 (2009
2. Hartyánszky I, Kalász H, Adeghate E, et al. Active metabolites resulting from decarboxylation, reduction and ester hydrolysis of parent drugs. Curr. Drug Metab. 13(6), 835-862 (2012
3. Hutzler J, Obach RS, Dalvie DK, Zientek MA. Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opin. Drug Metab. Toxicol. 9(2), 153-168 (2013
4. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol. Rev. 50(3), 387-412 (1998
5. Minagawa T, Nakano K, Furuta S, et al. Perspectives on non-clinical safety evaluation of drug metabolites through the JSOT workshop. J. Toxicol. Sci. 37(4), 667-673 (2012
6. Obach RS. Pharmacologically active drug metabolites: Impact on drug discovery and pharmacotherapy. Pharmacol. Rev. 65(2), 578-640 (2013
7. Yu H, Tweedie D. A perspective on the contribution of metabolites to drug drug interaction potential: The need to consider both circulating levels and inhibition potency. Drug Metab. Dispos. 41(3), 536-540 (2013
8. Timmerman P, Anders Kall M, Gordon B, et al. Best practices in a tiered approach to metabolite quantification: Views and recommendations of the European Bioanalysis Forum. Bioanalysis. 2(7), 1185-1194 (2010
9. Gao H, Jacobs A, White RE, Booth BP, Obach RS. Meeting report: Metabolites in Safety Testing (MIST) Symposium-Safety Assessment of Human Metabolites: What's really necessary to ascertain exposure coverage in safety tests? AAPS J. 15(4), 970-973 (2013
10. Li W, Zhang J, Tse FL. Strategies in quantitative LC-MS/MS analysis of unstable small molecules in biological matrices. Biomed. Chromatogr. 25(1-2), 258-277 (2011
11. D'Esposito F, Tattam BN, Ramzan I, Murray M. A liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 875(2), 522-530 (2008
12. Eriksson T, Björkman S. Handling of blood samples for determination of thalidomide. Clin. Chem. 43(6 Pt 1), 1094-1096 (1997
13. Sadilkova K, Gospe Jr SM, Hahn SH. Simultaneous determination of alpha-Aminoadipic semialdehyde, piperideine-6-carboxylate and pipecolic acid by LC-MS/MS for pyridoxine-dependent seizures and folinic acid-responsive seizures. J. Neurosci. Methods 184(1), 136-141 (2009
14. Sadagopan NP, Li W, Cook JA, et al. Investigation of EDTA anticoagulant in plasma to improve the throughput of liquid chromatography-Tandem mass spectrometric assays. Rapid Commun. Mass Spectrom. 17(10), 1065-1070 (2003
15. Yue B, Pattison E, Roberts WL, et al. Choline in whole blood and plasma: Sample preparation and stability. Clin. Chem. 54(3), 590-593 (2008
16. Chen J, Hsieh Y. Stabilizing drug molecules in biological samples. Ther. Drug Monit. 27(5), 617-624 (2005
17. Baranda AB, Alonso RM, Jiménez RM, Weinmann W. Instability of calcium channel antagonists during sample preparation for LC-MS-MS analysis of serum samples. Forensic Sci. Int. 156(1), 23-34 (2006
18. Hendriks G, Uges DRA, Franke JP. pH adjustment of human blood plasma prior to bioanalytical sample preparation. J. Pharm. Biomed. Anal. 47(1), 126-133 (2008
19. Meng M, Reuschel S, Bennett P. Identifying trends and developing solutions for incurred sample reanalysis failure investigations in a bioanalytical CRO. Bioanalysis 3(4), 449-465 (2011
20. Jemal M, Ouyang Z, Xia YQ. Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography. Biomed. Chromatogr. 24(1), 2-19 (2010
21. Dell D. Labile metabolites. Chromatographia Supplement 59(2), S139-S148 (2004
22. Krüger R, Vogeser M, Burghardt S, Vogelsberger R, Lackner KJ. Impact of glucuronide interferences on therapeutic drug monitoring of posaconazole by tandem mass spectrometry. Clin. Chem. Lab. Med. 48(12), 1723-1731 (2010
23. Li W, Fu Y, Flarakos J, Zhang D. LC-MS bioanalysis of ester prodrugs and other esterase labile molecules. In: Handbook of LC-MS Bioanalysis: Best Practice, Experimental Protocols and Regulations. Li W, Zhang J, Tse F (Eds). Wiley & Sons, Inc., Hoboken, NJ, USA, 431-445 (2013
24. Vainchtein LD, Rosing H, Mirejovsky D, Lenaz L, Schellens JH, Beijnen JH. Stability experiments in human urine with EO9 (apaziquone): A novel anticancer agent for the intravesical treatment of bladder cancer. J. Pharm. Biomed. Anal. 43(1), 285-292 (2007
25. Kamei T, Uchimura T, Nishimiya K, Kawanishi T. Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC-MS/MS, and its application in a clinical trial. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879(30), 3415-3422 (2011
26. Chang Q, Chow MS, Zuo Z. Studies on the influence of esterase inhibitor to the pharmacokinetic profiles of oseltamivir and oseltamivir carboxylate in rats using an improved LC-MS/MS method. Biomed. Chromatogr. 23(8), 852-857 (2009
27. Zeng J, Onthank D, Crane P, et al. Simultaneous determination of a selective adenosine 2A agonist, BMS-068645, and its acid metabolite in human plasma by liquid chromatography-Tandem mass spectrometry-evaluation of the esterase inhibitor, diisopropyl fluorophosphate, in the stabilization of a labile ester-containing drug. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852(1-2), 77-84 (2007
28. Tang C, Sojinu OS. Simultaneous determination of caffeic acid phenethyl ester and its metabolite caffeic acid in dog plasma using liquid chromatography-Tandem mass spectrometry. Talanta 94, 232-239 (2012
29. Wang X, Bowman PD, Kerwin SM, Stavchansky S. Stability of caffeic acid phenethyl ester and its fluorinated derivative in rat plasma. Biomed. Chromatogr. 21(4), 343-350 (2007
30. Salem II, Alkhatib M, Najib N. LC-MS/MS determination of betamethasone and its phosphate and acetate esters in human plasma after sample stabilization. J. Pharm. Biomed. Anal. 56(5), 983-991 (2011
31. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 24(1), 49-65 (2010
32. Heinig K, Wirz T, Bucheli F, Gajate-Perez A. Determination of oseltamivir (Tamiflu®) and oseltamivir carboxylate in dried blood spots using offline or online extraction. Bioanalysis 3(4), 421-372 (2011
33. D'Arienzo CJ, Ji QC, Discenza L, et al. DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors. Bioanalysis 2(8), 1415-1422 (2010
34. Eikel D, Henion JD. Liquid extraction surface analysis (LESA) of food surfaces employing chip-based nano-electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 25(16), 2345-2354 (2011
35. Eikel D, Vavrek M, Smith S, et al. Liquid extraction surface analysis mass spectrometry (LESA-MS) as a novel profiling tool for drug distribution and metabolism analysis: The terfenadine example. Rapid Commun. Mass Spectrom. 25(23), 3587-3596 (2011
36. Schadt S, Kallbach S, Almeida R, Sandel J. Investigation of figopitant and its metabolites in rat tissue by combining whole-body autoradiography with liquid extraction surface analysis mass spectrometry. Drug Metab. Dispos. 40(3), 419-425 (2012
37. Kertesz V, Van Berkel GJ. Automated liquid microjunction surface sampling-HPLC-MS/MS analysis of drugs and metabolites in whole-body thin tissue sections. Bioanalysis 5(7), 819-826 (2013
38. Wisztorski M, Fatou B, Franck J, et al. Microproteomics by liquid extraction surface analysis: Application to FFPE tissue to study the fimbria region of tubo-ovarian cancer. Proteomics Clin. Appl. 7(3-4), 234-240 (2013
39. Hamilton R, Garnett W, Kline B. Determination of mean valproic acid serum level by assay of a single pooled sample, Clin. Pharmacol. Ther. 29(3), 408-413 (1981
40. Dalvie DK, Zhang C, Chen W, Smolarek T, Obach RS, Loi C-M. Cross species comparison of the metabolism and excretion of zoniporide: Contribution of aldehyde oxidase to interspecies differences. Drug Metab. Dispos. 38(4), 641-654 (2010
41. Diamond S, Boer J, Maduskuie TP, Falahatpisheh N, Li Y, Yeleswaram S. Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab. Dispos. 38(8), 1277-1285 (2010